Status:
SUSPENDED
Screening of Pulmonary Hypertension in Methamphetamine Abusers
Lead Sponsor:
The University of Hong Kong
Conditions:
Methamphetamine Abuse
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Methamphetamine is misuse if classified as a "likely" risk factor for pulmonary arterial hypertension (PAH). Nevertheless the actual prevalence of and a screening strategy for PAH in methamphetamine u...
Detailed Description
Methamphetamine is a potent central nervous system stimulant originally prescribed for individuals with neuropsychiatric diseases. Owing to its highly addictive nature, illicit use has emerged as a ma...
Eligibility Criteria
Inclusion
- \>= 18 years at enrollment
- report of methamphetamine use in the last 2 years
- diagnosed as amphetamine dependent according to the Diagnostic and Statistical Manual of Mental Disorders (the 5th edition) (DSM-V)(13)
- voluntarily agree to participate by providing written informed consent
Exclusion
- failed or refused to provide written informed consent
- Reference:
- 13\. Battle DE. Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas 2013;25(2):191-2.
Key Trial Info
Start Date :
December 23 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 22 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04019600
Start Date
December 23 2019
End Date
December 22 2022
Last Update
August 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong